Aurobindo chalks up new FDA manufacturing concerns

Aurobindo
The list of Aurobindo plants having to fix issues flagged by the FDA continues to grow. (Aurobindo)

India’s Aurobindo, which has been racking up FDA actions right and left, acknowledged Monday a recent agency inspection resulted in a Form 483. 

The drugmaker, in a public filing Monday, admitted (PDF) its Unit 7 was issued the citation with seven observations following an inspection last month. The company provided no details but noted none of the observations are related to data integrity and it believes it can quickly deal with the issues raised.

RELATED: Aurobindo gets warning letter over valsartan recall mess 

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

But Aurobindo already has a lot of manufacturing improvements that it is making at other plants. The FDA uncovered issues with data integrity this year at two Aurobindo plants in Telangana, a sterile drug plant and a finished dose plant.  

A few weeks later, the FDA issued a warning letter to Aurobindo’s plant in the Srikakulam district for issues the FDA said contributed to its valsartan products being tainted with N-nitrosodiethylamine, a suspected carcinogen that was detected in blood pressure meds last year. The inspection of the plant in February came just weeks after Aurobindo recalled 80 lots of valsartan.

Aurobindo placed the blame for the problem on ingredients it bought from a contractor and poor cleaning procedures. The FDA criticized the company for failing to get to the root cause of the issue. It also said Aurobindo did not initially let the FDA know about some changes in its processes that may have contributed to the presence of the impurities it uncovered.

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.